Sermorelin
What to know about Sermorelin: uses, side effects, interactions, and safety considerations for people taking it or caring for someone who is.
Sermorelin is classified as Low risk (2 risk points) by AllMeds. GHRH analogue. Previously FDA approved then withdrawn. Used via compounding.
Key Takeaways
- Risk level: Low (2 points)
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | Unscheduled | Not PBS listed |
Risk Profile
GHRH analogue. Previously FDA approved then withdrawn. Used via compounding.
How Sermorelin is regulated
Sermorelin is overseen by medicines regulators in each country. The rules below explain how it's scheduled, what oversight applies, and what to discuss with your doctor or pharmacist before starting, changing, or stopping this medication.
Australia TGA / PBS / State Schemes
Classified as Unscheduled under the Therapeutic Goods Administration (TGA).
Clinical Evidence
- Sermorelin (Geref) — Previously FDA Approved, Now Discontinued (2008)
Sermorelin (Geref) was FDA-approved for GH deficiency diagnosis and treatment. Voluntarily withdrawn from market in 2008 for commercial reasons, not safety.
Was FDA-approved — withdrawal was commercial, not safety-related
Check this medication against your full medication list
Run a full risk assessment including Sermorelin interactions and compliance checks.
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile in minutes. Free for individuals; team plans for case managers, insurers, and schemes.
Important: This page is general health information, not personal medical advice. If you have questions about your medication — including starting it, stopping it, changing the dose, or combining it with something else — speak with your doctor or pharmacist. For an emergency or suspected overdose, call your local emergency number or poison information service immediately. Information is drawn from regulator and clinical guideline sources (TGA, FDA, MHRA, NICE, PBS, CDC); see our methodology for details.